Aditxt, Inc. (NASDAQ:ADTX – Get Free Report) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,000 shares, an increase of 150.0% from the October 15th total of 400 shares. Based on an average daily trading volume, of 227,900 shares, the short-interest ratio is currently 0.0 days. Approximately 0.5% of the shares of the company are short sold.
Analysts Set New Price Targets
Separately, HC Wainwright lifted their target price on shares of Aditxt to $61.00 and gave the stock a “buy” rating in a research report on Wednesday, September 6th.
Insider Buying and Selling
Institutional Trading of Aditxt
A hedge fund recently bought a new stake in Aditxt stock. Bank of New York Mellon Corp acquired a new position in Aditxt, Inc. (NASDAQ:ADTX – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 34,968 shares of the company’s stock, valued at approximately $119,000. Bank of New York Mellon Corp owned 2.99% of Aditxt at the end of the most recent reporting period.
Aditxt Trading Down 4.3 %
Aditxt stock opened at $4.17 on Friday. The firm has a 50-day moving average of $13.95 and a 200-day moving average of $22.44. Aditxt has a 1-year low of $4.08 and a 1-year high of $78.40.
Aditxt (NASDAQ:ADTX – Get Free Report) last posted its earnings results on Monday, August 14th. The company reported ($36.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($115.60) by $78.80. The company had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.36 million. Aditxt had a negative net margin of 2,891.14% and a negative return on equity of 777.58%. On average, analysts expect that Aditxt will post -235.2 earnings per share for the current year.
Aditxt, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.
- Five stocks we like better than Aditxt
- How to Invest in EV Charging Stations
- Data giants MongoDB and Snowflake just got upgraded
- Pros And Cons Of Monthly Dividend Stocks
- Plug Power at tipping point; it’s make or break time for hydrogen
- With Risk Tolerance, One Size Does Not Fit All
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.